Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Ranolazine»


Pronunciation: (ra-NOE-la-zeen)Class: Antianginal agent

Trade Names:Ranexa- Tablets, ER 500 mg- Tablets, ER 1,000 mg


Mechanism of action unknown. Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or BP.



T max is 2 to 5 h. Mean steady-state C max is 2,600 ng/mL (range, 400 to 6,100 ng/mL), and is usually attained within 3 days of twice-daily dosing. Bioavailability from oral solution is about 76%.


Protein binding is approximately 62%.


Extensively metabolized in the gut and the liver with less than 5% excreted unchanged. Primarily metabolized by CYP3A and, to a lesser extent, by CYP2D6.


Apparent terminal half-life is 7 h. Approximately 75% is excreted in the urine and 25% in the feces.

Special Populations

Renal Function Impairment

Plasma levels increase up to 50%.

Hepatic Function Impairment

Increased plasma levels in patients with mild and moderate hepatic function impairment.

Indications and Usage

Treatment of chronic angina.


Patients taking strong CYP3A inhibitors; patients taking CYP3A inducers; clinically important hepatic function impairment.

Dosage and Administration


PO 500 mg twice daily. May increase to 1,000 mg twice daily, based on symptoms (max, 2,000 mg/day).

Dose ModificationAdults

PO Limit the max dosage to 500 mg twice daily in patients receiving diltiazem, verapamil, and other moderate CYP3A inhibitors. Down-titrate the dose based on clinical response in patients receiving P-glycoprotein inhibitors (eg, cyclosporine).

General Advice

  • May be used in combination with amlodipine, beta-blockers, or nitrates.
  • Administer without regard to meals. Administer with food if GI upset occurs.
  • Advise patient to swallow tablet whole and not to crush, chew, or break.


Store tablets at controlled room temperature (59° to 86°F).

Drug Interactions

Drugs metabolized by CYP2D6 (eg, tricyclic antidepressants [eg, amitriptyline])

Studies have not been conducted; however, ranolazine may inhibit metabolism of these agents, necessitating a decrease in dose of CYP2D6 substrates.

Drugs metabolized by CYP3A (eg, simvastatin)

Plasma levels may be increased by ranolazine; however, dosage adjustments do not appear to be necessary.

Drugs transported by P-glycoprotein (eg, digoxin)

Plasma levels may be elevated by ranolazine. Dosage adjustment may be needed.

Inducers of CYP3A (carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) and P-glycoprotein (eg, rifampin, St. John's wort)

Ranolazine plasma concentrations may be decreased. Avoid coadministration with ranolazine.

Inhibitors of CYP2D6 (eg, paroxetine)

Ranolazine plasma concentrations may be increased. However, ranolazine dosage adjustment does not appear to be necessary.

Moderate CYP3A inhibitors (eg, aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice or grapefruit-containing products, verapamil)

Ranolazine plasma concentrations may be increased. Limit the ranolazine dosage to 500 mg twice daily.

P-glycoprotein inhibitors (eg, cyclosporine)

Ranolazine plasma concentrations may be increased. Down-titrate the ranolazine dose based on clinical response.

Strong CYP3A inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir)

Ranolazine plasma concentrations may be increased. Coadministration with ranolazine is contraindicated.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Bradycardia, hypotension, orthostatic hypotension, palpitations (2% or less); dose-related QTc interval prolongation.


Dizziness, headache (6%).


Tinnitus, vertigo (2% or less).


Constipation (5%); nausea (4%); abdominal pain, dry mouth, vomiting (2% or less).


Leukopenia, pancytopenia, thrombocytopenia.




Dyspnea (2% or less).


Peripheral edema (2% or less).



Obtain baseline and follow-up ECGs to evaluate effects of ranolazine on QT interval. Monitor BP after initiating therapy in patients with severe renal function impairment.


Category C .




Safety and efficacy not established.


Use caution when selecting dose, usually starting at the lower end of the dosing range, reflecting the greater frequency of hepatic and renal function impairment and comorbidity.

Renal Function

Plasma concentrations may be increased up to 50%.

Hepatic Function

Plasma concentrations may increase in patients with mild and moderate hepatic function impairment by 30% and 60%, respectively. Contraindicated in patients with clinically significant hepatic function impairment.

QT prolongation

Ranolazine prolongs the QTc interval in a dose-related manner. There is little experience with dosages above 1,000 mg twice daily, high exposure, other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval.

Tumor promotion

Ranolazine has been reported to promote tumor formation and progression to malignancy in mice.



Confusion, diplopia, dizziness, nausea, paresthesia, syncope, vomiting.

Patient Information

  • Ensure that patient understands that ranolazine is taken daily to reduce the frequency of angina attacks and is not to be used to treat an acute angina episode.
  • Advise patient to review the Patient Information leaflet carefully before starting therapy and to reread and check for new information each time the medication is refilled.
  • Advise patient that ranolazine may be used in combination with at least 1 other antianginal medication and to continue to take other antianginal medications as prescribed by health care provider.
  • Caution patient to take exactly as prescribed and not to change the dose or stop taking unless advised by health care provider.
  • Caution patient that max daily dosage is 1,000 mg twice daily and to never exceed that amount because of the risk of serious toxicity.
  • Advise patient to take each dose without regard to meals, but to take with food if GI upset occurs.
  • Caution patient to swallow tablets whole and not to crush, chew, or break.
  • Caution patient to avoid grapefruit juice and grapefruit-containing products while taking ranolazine.
  • Review with patient and family the signs and symptoms of angina (eg, acute onset of pressure-like chest pain that may radiate down the left arm and/or into the neck or jaw, often associated with sweating and shortness of breath or difficulty breathing).
  • Ensure that patient has SL nitroglycerin available at all times, knows when and how to use SL nitroglycerin, and knows what to do if angina pain worsens or fails to respond to SL nitroglycerin.
  • Advise patient to notify health care provider if angina symptoms increase in frequency or severity, or if there is a sudden increase in the frequency of use of SL nitroglycerin.
  • Caution patient that medication may cause dizziness or light-headedness, and to use caution while driving or performing other tasks requiring alertness or coordination until tolerance is determined.
  • Advise patient to discontinue therapy and contact health care provider immediately if any of the following occur: difficulty breathing, fainting, hives, itching, palpitations, skin rash, or unexplained shortness of breath.

Copyright © 2009 Wolters Kluwer Health.

  • Ranolazine MedFacts Consumer Leaflet (Wolters Kluwer)
  • ranolazine Advanced Consumer (Micromedex) - Includes Dosage Information
  • Ranexa Prescribing Information (FDA)
  • Ranexa Consumer Overview

See Also...